Denil Nanji Shekhat - Jun 18, 2024 Form 4 Insider Report for MIRA PHARMACEUTICALS, INC. (MIRA)

Role
Director
Signature
/s/ Denil Shekhat
Stock symbol
MIRA
Transactions as of
Jun 18, 2024
Transactions value $
$0
Form type
4
Date filed
6/21/2024, 04:30 PM
Previous filing
Mar 27, 2024
Next filing
Dec 10, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MIRA Nonqualified Stock Option (right to buy) Award $0 +50K $0.00 41.7K Jun 18, 2024 Common Stock 50K $0.71 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The exercise price of the stock options issued to the Reporting Person is equal to the Nasdaq Official Closing Price of the Issuer's common stock on June 18, 2024, the date of the grant.
F2 The stock options were issued to the Reporting Person on June 18, 2024, pursuant to a grant under the Issuer's 2022 Omnibus Incentive Plan, as amended and restated (the "Plan"), and in accordance with the terms of a consulting agreement dated June 18, 2024, by and between the Reporting Person and MIRA Pharmaceuticals, Inc. The stock options will vest in three equal tranches, with the first tranche vesting immediately on the grant date of June 18, 2024, the second tranche vesting on December 18, 2024, and the final tranche vesting on June 18, 2025.
F3 Represents (i) 25,000 stock options that were issued to the Reporting person on March 25, 2024, that were vested in full and became exercisable on the same date, pursuant to a grant under the Plan at an exercise price of $1.16 each and (ii) 16,666 stock options that were issued to the Reporting Person on June 18, 2024, that were vested in full and became exercisable on the same date, pursuant to a grant under the Plan at an exercise price of $0.71 each.